- Which models will see the most uptake over the next five years?
- For which phases of development are certain monitoring models best suited?
- What are the barriers to overcome in order to increase the adoption of new monitoring models?
- Where will outsourced monitors come from in the future?
Report Contents:
- The changing times – Clinical monitoring is critically important to the drug development process, no question. But that does not mean it is a static process. This section provides evidence that times are changing and new clinical monitoring models have a place in the industry.
- The changing models – This section focuses on the industry’s perspectives on which models are likely to be adopted and for which phases of development they are most appropriate. Barriers to adoption are addressed as are economic models preferences.
- Why change? – Gives an overview of why it is going to be difficult to increase the adoption of newer monitoring models.